MDS in the Lower-risk Patient: The Current Treatment Algorithm

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: April 15, 2020
Expiration Date: April 15, 2021

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

How is low-risk MDS identified and treated today in your practice? Read a recent interview with Dr. Hetty Carraway where she discusses lower-risk myelodysplastic syndromes (MDS) defined by the International Prognostic Scoring System (IPSS) and an updated “revised” version (IPSS-R). In this discussion, Dr. Carraway provides readers with an overview of current standards of care and where the newly approved agent luspatercept fits in the treatment paradigm.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe patient- and disease-related factors that should be considered when developing treatment strategies for lower-risk MDS patients, including the presence of symptomatic anemia and/or the del5q mutation
  • Identify currently available, new and emerging agents with efficacy in managing lower-risk MDS or associated disease-related conditions
  • Outline a treatment algorithm for patients with lower-risk MDS based on key patient- and disease-related factors

Agenda

MDS in the Lower-risk Patient: The Current Treatment Algorithm – Hetty E. Carraway, MD, MBA, FACP

Instructions for Participation and Credit

This activity is eligible for credit through April 15, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Hetty E. Carraway, MD, MBA, FACP
Associate Professor of Medicine
Vice Chair, Strategy and Enterprise Development
Hematologic Oncology and Blood Disorders
Taussig Cancer Institute, Cleveland Clinic
Cleveland, Ohio

Dr. Hetty Caraway received her medical degree from the University of Massachusetts Medical School in Worcester, Massachusetts. She completed her internship and residency in internal medicine, and her fellowship in medical oncology at Johns Hopkins University in Baltimore. In addition to her medical training, Dr. Carraway earned an MBA from the Carey Business School at Johns Hopkins University in the Business of Health. She is currently a Staff Associate Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Vice Chair of Strategy and Enterprise Development at the Taussig Cancer Institute in the Division of Hematologic Oncology and Blood Disorders at the Cleveland Clinic.

Dr. Carraway is American Board of Internal Medicine certified in medical oncology and internal medicine. She is a member of numerous professional organizations including the American Society of Hematology (ASH), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Eastern Cooperative Oncology Group (ECOG), SWOG, and the America College of Physicians, among others. Dr. Carraway has co-authored numerous peer-¬reviewed publications, review articles, editorials, abstracts and book chapters. She is nationally sought for her expertise in hematologic malignancies (AML, ALL and MDS). As a translational clinical scientist, Dr. Carraway’s research is focused on experimental therapeutics of acute leukemias and myeloproliferative diseases.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-013-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Hetty Carraway has received honoraria related to speakers’ bureau activities from Agios, Celgene Corporation, Jazz Pharmaceuticals plc, Novartis AG, and Stemline Therapeutics, Inc.; formal advisory activities from Agios, Celgene, Jazz, and Novartis; and consultant fees from Agios and Celgene. She has received grant support related to research activities from Celgene. She has also disclosed a financial relationship with AbbVie Inc., Astex Pharmaceuticals, and Takeda Oncology.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.